A recent study involving the compound DOI showed promising results in mice.
A recent study involving the compound DOI showed promising results in mice.
The FDA requested additional trial data, with researchers eager to continue psychedelic trials.
Five treatment centers would offer psychedelic therapy for veterans and former first responders.
A Maryland taskforce will plan regulation, while Arizona will tentatively cover MDMA treatment for first responders with PTSD.
Connecticut, Missouri, and New Hampshire join 10 other states considering psychedelics bills.
States so far include Alaska, Arizona, California, Hawaii, Indiana, Illinois, Massachusetts, Maryland, New Jersey, and Wisconsin.
The ketamine molecule is not FDA-approved in any formulation for the treatment of psychiatric disorders.
Clinical research indicates the potential for strong mental health applications.
These guidelines advise researchers on study design and other considerations as they develop medications that contain psychedelics.
